"Our small molecule drug discovery project was seeking a robust assay allowing to screen against the target of interest expressed in its natural cellular environment.
Pelago Bioscience's expertise in drug discovery projects, specifically in the CETSA platform and high throughput screens was the key to achieving our goals.
We found Pelago's team to be professional, knowledgeable, flexible and dedicated. We highly recommend Pelago Bioscience for drug discovery projects."
Po-Shun Lee, Chief Medical Officer
Generian
"Chemoproteomics is like taking a watch to pieces and counting the cogs – it doesn't tell you which cogs drive which process and how the wider system works. This is why using CETSA can add so much value to your target identification studies."
Pär Nordlund, Professor and Inventor of CETSA
Karolinska Institute
"CETSA data is a keystone in our SAR analysis, and by assessing cellular target engagement of our compounds across multiple cell lines we gain confidence in our project prioritizations."
Peter Joyce, CEO and Co-Founder
Grey Wolf Therapeutics
"Pelago Bioscience offers exceptional technical expertise in all aspects of target deconvolution using
CETSA – including study design, sample preparation, LC-MS data acquisition, and statistical processing.
Our collaboration always proceeded effectively due to Pelago Bioscience's responsiveness, scientific commitment, and dedication to clients resulting in delivery of impactful scientific results."
Benjamin Fontaine, Senior Scientist
LifeMine Therapeutics
"Using our world leading expertise in CETSA we have created a faster and more efficient drug discovery process. We take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help."
Michael Dabrowski, CEO and Co-founder
Pelago Bioscience
"While ligand binding assays are commonly used for PK/PD studies in clinical trials of biologics and endogenous protein quantification, Lipum AB sought to establish an orthogonal quantitative LC-MS/MS method for our target protein, bile salt-stimulated lipase (BSSL). We chose Pelago Bioscience as our partner due to their rapid project initiation, collaborative approach, and extensive expertise in processing complex biological samples using high-resolution mass spectrometry. Working with one of the best proteomics labs in the Nordics, Pelago's team delivered high-quality results that aligned perfectly with our clinical research goals."
Ola Sandborgh, CEO
Lipum AB
“As we approached late preclinical development, our lead compound demonstrated strong efficacy and a favorable toxicity profile.Partnering with Pelago Bioscience, we leveraged their expertise in CETSA technology to successfully identify and validate the protein target. With the comprehensive data package they provided, we met investor requirements and gained the support needed to move forward. The Pelago team´s swift and precise response was invaluable throughout the process, and their scientific excellence made a real difference. We’re highly encouraged by the results and grateful for their outstanding collaboration.”
Martin Bonde, CEO
Inthera Bioscience AG
